Buscar
Congreso SOLACI

Búsqueda de: heparina

Si no está conforme con los resultados, inténtelo de nuevamente.
Day 4

BRAVO 3: Heparina vs Bivalirudina en pacientes que reciben TAVI

Original article Thierry Lefevre
solaci -
Ir
Acute coronary syndromes

Heparin Pretreatment in STEACS Treatment: A New Old Ally?

The treatment of ST-segment elevation acute coronary syndromes (STEACS) is undoubtedly reperfusion therapy with primary percutaneous coronary...
solaci -
Ir
Antithrombotic Anticoagulants

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on...
solaci -
Ir
Scientific Articles COVID-19

Heparin Anticoagulation in Critically Ill COVID-19 Patients: Results that Differ from the Rest

In critically ill COVID-19 patients, an initial strategy of anticoagulation with heparin did not result in any...
solaci -
Ir
Scientific Articles COVID-19

Surviving Covid-19 with Good Old Heparin?

Patients hospitalized for COVID-19 are at high risk for thrombosis, particularly venous thromboembolism. This information is not...
solaci -
Ir
Scientific Articles COVID-19

Anticoagulation with Heparin in Non-Critical COVID-19

In non-severe COVID-19 patients, an initial therapeutic strategy with heparin increases the chance of survival after discharge...
solaci -
Ir
Clinical Cases

The Fellow’s Corner | 2nd Clinical Case: An Explosive Mission

Read the case presentation and join the conversation through the comments in this post! Case Introduction: An Explosive...
solaci -
Ir
Antithrombotic Anticoagulants

Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava. The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15%...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad